HKU Scholars Hub: Browsing DSpace

Browsing by Author Cathcart, A

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 7 of 7

	Title	Author(s)	Issue Date	Views
	A phase 1 study evaluating the neutralizing, vaccinal monoclonal antibody VIR-3434 in participants with chronic hepatitis B virus infection Proceeding/Conference:Journal of Hepatology	Agarwal, K Yuen, RMF Wedemeyer, H Cloutier, D Shen, L Arizpe, A Pang, P Tay, C Gupta, SV Cathcart, A Gane, E	2021	27
	Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody. Poster Presentation (SAT837) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Agarwal, A Yuen, RMF Wedemeyer, H Cloutier, D Shen, L Arizpe, A Gupta, SV Fanget, MC Seu, J Cathcart, A Lau, AH Hwang, C Gane, EJ	2022	2
	Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection. Oral Presentation (OS090) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Lim, YS Yuen, RMF Cloutier, D Thanawala, V Shen, L Gupta, SV Arizpe, A Cathcart, A Hwang, C Gane, EJ	2022
	Preliminary on-treatment data from a phase 2 study evaluating VIR-2218 in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection Proceeding/Conference:Journal of Hepatology	Yuen, RMF Lim, YS Cloutier, D Shen, L Arizpe, A Pang, P Tay, C Thanawala, V Gupta, SV Cathcart, A Gane, E	2021
	Preliminary results of a Phase 2 study of VIR-2218, an X-targeting RNAi therapeutic, in patients with chronic hepatitis B: sub-analyses of HBeAg-negative and HBeAg-positive patients Proceeding/Conference:Hepatology International	Yuen, RMF Lim, YS Cloutier, D Shen, L Cathcart, A Ding, X Arizpe, A Pang, P Huang, S Gane, E	2021	15
	Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results Proceeding/Conference:Journal of Hepatology	Gane, E Lim, YS Cloutier, D Shen, L Cathcart, A Ding, X Pang, P Huang, S Yuen, RMF	2021
	Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B Proceeding/Conference:Hepatology	Chan, HLY Lim, YS Seto, WKW Agarwal, K Brunetto, MR Janssen, HLA Caruntu, F Stepanova, T Tsang, O Yatsuhashi, H Tak, WY Chen, CY Celen, M Sun, V Flaherty, JF Lin, L Cathcart, A Gaggar, A Pan, CQ Shalimar Buti, M	2018

Showing results 1 to 7 of 7